Precision BioSciences Presents Preclinical Data Highlighting Capabilities of ARCUS for Gene Insertion and Excision at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress
Thursday, October 26, 2023 BiopharmaWatch Research 1 min read
Key Takeaway: Precision BioSciences presented preclinical data at the ESGCT 30th Annual Congress, showcasing the capabilities of its ARCUS technology for gene insertion and excision. The data highlighted ARCUS's high-efficiency gene insertion in non-human primates and its ability to achieve large gene excisions, resulting in significant muscle improvement in a Duchenne Muscular Dystrophy mouse model.
Price reaction · baseline $8.577 (2023-10-25 close) · hit pre-market · clean, no other DTIL news in the window
Data shows significant functional muscle improvement in a DMD mouse model.
ARCUS was compared favorably to CRISPR-Cas9 in gene insertion.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer
Full Press Release Details
– ARCUS showed durable, high-efficiency gene insertion capabilities in NHPs and comparison to CRISPR-Cas9 – Data demonstrates ability of ARCUS to achieve large gene excisions enabling significant functional muscle improvement in a DMD mouse model DURHAM, N.C. –(BUSINESS WIRE)–Oct.
Frequently Asked Questions
What is ARCUS technology?
ARCUS technology is a gene editing platform developed by Precision BioSciences.
What were the results of the ARCUS study?
The study showed high-efficiency gene insertion and significant muscle improvement in a DMD mouse model.
How does ARCUS compare to CRISPR-Cas9?
ARCUS demonstrated superior gene insertion capabilities compared to CRISPR-Cas9 in the study.
Where was the data presented?
The data was presented at the European Society of Gene & Cell Therapy Congress.